After years of tussling in negotiations between CMS and pharmaceutical companies, 10 drugs in the Medicare Drug Price Negotiation Program in Medicare Part D will have new, lower prices starting in CY2026.
But, the Wall Street Journal notes, there’s more to come. By Feb. 1, the federal government will select 15 more drugs for negotiation. Among the drugs under consideration, the WSJ reports, is Wegovy.
The manufacturers have some more asks for the next round of talks, including more information on how CMS picked medicines used for comparison in the pricing of the drugs. Read more about NCPA’s stance on the negotiations here.
NCPA
